menu
    • menu
    [{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Daridorexant Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Daridorexant Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Daridorexant Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Daridorexant Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Holling Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Daridorexant Hydrochloride","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Holling Bio-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Holling Bio-Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Daridorexant Hydrochloride

    Menu

    Daridorexant Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Holling Bio-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

                            Details : Under the agreement, Nxera will be responsible for the supply of Quviviq (Daridorexant HCl) & Holling will be responsible for regulatory, commercial activities and will hold all regulatory approvals.

                            Product Name : Quviviq

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 28, 2025

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Holling Bio-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Shionogi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

                            Details : Quviviq (daridorexant Hcl) is a OX1R/OX2R inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of insomnia in adults.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 18, 2024

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Shionogi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nxera Enrolls First Insomnia Patient for Phase 3 Trial Of Daridorexant in South Korea

                            Details : Quviviq (daridorexant) is a dual orexin receptor antagonist. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of adult patients with insomnia.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 04, 2024

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Shionogi

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan

                            Details : Under the partnership, Nxera will be responsible for providing Quviviq (daridorexant) for the Japanese market, and Shionogi will be exclusively responsible for distribution and sales in Japan.

                            Product Name : Quviviq

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Shionogi

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nxera Pharma Gains Approval for QUVIVIQ in Japan to Treat Insomnia

                            Details : Quviviq (daridorexant) is a dual orexin receptor antagonist. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of adult patients with insomnia.

                            Product Name : Quviviq

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 23, 2024

                            Lead Product(s) : Daridorexant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth